AltraVax, Inc., a new, privately-held biopharmaceutical company, has acquired a vaccine development technology package from Maxygen, Inc. (Nasdaq: MAXY) that gives AltraVax an exclusive license to develop vaccines for infectious diseases and is targeting influenza, a treatment for hepatitis B and HIV. Under the terms of the licensing agreement, AltraVax has exclusive rights to use Maxygen’s proprietary MolecularBreeding™ technology platform in its infectious disease vaccine development programs, subject to rights retained by Maxygen… (Source: Health News from Medical News Today)
Further information:
Related posts:
- Arrhythmia Research Technology and Nihon Kohden Sign Multi-Year License Agreement for Predictor(TM) SAECG Software
- Zecotek’s Green Fiber Laser Technology Platform Highlighted at Laser and Photonics Marketplace in San Francisco
- Cancer Research UK And Immatics Biotechnologies To Trial Vaccine For Brain Cancer
- Johns Hopkins Medicine Acquires Naviscan PEM Technology For Novel Radiotracer Research
- Tom Packert Has Joined CareCloud as Chief Technology Officer
Posted in